New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
08:01 EDTABBVAbbVie presents results from Phase 1 study with ABT-414
AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme. Specifically, one patient experienced a complete response (CR) and three patients experienced partial responses as measured with the Revised Assessment in Neuro-Oncology criteria. Later stage clinical trials are being planned to continue to investigate ABT-414 in patients with glioblastoma multiforme.
News For ABBV From The Last 14 Days
Check below for free stories on ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 8, 2014
07:48 EDTABBVCredit Suisse remains a buyer of AbbVie
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use